Randrianarison-Jewtoukoff V, Perricaudet M
Unité de Génétique des Virus Oncogénes, CNRS URA 1301, Institut Gustave Roussy, Villejuif, France.
Biologicals. 1995 Jun;23(2):145-57. doi: 10.1006/biol.1995.0025.
Over the past 15 years, advances in molecular biology have permitted in vitro and in vivo gene transfer into mammalian cells. Genetically engineered microorganisms are highly promising developments for gene therapy and the future of vaccines. Such vectors constitute genuine tools for high level expression of heterologous genes for both therapeutic and induced immunity applications. Several vector systems have emerged with different relative advantages and limits depending on the proposed application. Adenovirus (Ad) has gained our interest, and in this review we focus on its applicability as a vaccine vector. We describe its potentials, as well as some of the foreseen obstacles related essentially to its use in preventive medicine.
在过去15年里，分子生物学的进展使得在体外和体内将基因转移到哺乳动物细胞成为可能。基因工程微生物对于基因治疗和疫苗的未来发展来说是非常有前景的进展。这类载体构成了用于治疗和诱导免疫应用中异源基因高水平表达的真正工具。根据所提议的应用，已经出现了几种具有不同相对优势和局限性的载体系统。腺病毒（Ad）引起了我们的关注，在本综述中，我们将重点关注其作为疫苗载体的适用性。我们描述了它的潜力，以及一些主要与在预防医学中的使用相关的可预见障碍。
